P-Cure Ltd., an Israeli startup for proton therapy has received U.S. Food and Drug Administration (FDA) approval for its patented upright imaging solution. The P-Cure system is based on a diagnostic-quality computed tomography (CT) enabling treatment for cancer patients in a seated position.
P-Cure’s first product was cleared by the FDA in 2010.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at office@jewishbusinessnews.com.
Thank you.
“The benefits of treating patients in a seated position include greater patient comfort, less internal organ movement, better saliva drainage and a better position for breathing for asthmatic and other patients experiencing impaired breathing. It may also deliver less collateral radiation to sensitive organs while enabling greater accuracy in proton beam delivery, ” Said Michael Marash, Ph.D., founder and CEO of P-Cure.
In addition, the company said in a press release, there are also significant economic advantages to treating patients in a seated position including the capital cost of equipment and construction, .
